# John T. Lear

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/john-t-lear/

## Facts

| Field | Value |
| --- | --- |
| Citations | 8,769 |
| Field | Nonmelanoma Skin Cancer Studies |
| h-index | 49 |
| i10-index | 143 |
| Last Known Institution | Salford Royal Hospital |
| OpenAlex ID | https://openalex.org/A5084705734 |
| ORCID iD | 0000-0002-2969-9922 |
| Works | 264 |

## Researcher papers

- [Non-melanoma skin cancer](https://scholariq.org/papers/non-melanoma-skin-cancer/)
- [Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial](https://scholariq.org/papers/treatment-with-two-different-doses-of-sonidegib-in-patients-with-locally/)
- [Association between functional polymorphism in EGF gene and malignant melanoma](https://scholariq.org/papers/association-between-functional-polymorphism-in-egf-gene-and-malignant-melanoma/)
- [British Association of Dermatologists' guidelines for the management of onychomycosis 2014](https://scholariq.org/papers/british-association-of-dermatologists-guidelines-for-the-management-of/)
- [Intraindividual, right-left comparison of topical methyl aminolaevulinate-photodynamic therapy and cryotherapy in subjects with actinic keratoses: a multicentre, randomized controlled study](https://scholariq.org/papers/intraindividual-right-left-comparison-of-topical-methyl-aminolaevulinate/)
- [Long‐term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma: 42‐month analysis of the phase II randomized, double‐blind BOLT study](https://scholariq.org/papers/long-term-efficacy-and-safety-of-sonidegib-in-patients-with-advanced-basal-cell/)
- [Long‐term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30‐month analysis of the randomized phase 2 BOLT study](https://scholariq.org/papers/long-term-efficacy-and-safety-of-sonidegib-in-patients-with-locally-advanced-and/)
- [Vitamin D receptor polymorphisms are associated with altered prognosis in patients with malignant melanoma.](https://scholariq.org/papers/vitamin-d-receptor-polymorphisms-are-associated-with-altered-prognosis-in/)
- [Risk Factors for Basal Cell Carcinoma in the UK: Case-Control Study in 806 Patients](https://scholariq.org/papers/risk-factors-for-basal-cell-carcinoma-in-the-uk-case-control-study-in-806/)
- [Sonidegib and vismodegib in the treatment of patients with locally advanced basal cell carcinoma: a joint expert opinion](https://scholariq.org/papers/sonidegib-and-vismodegib-in-the-treatment-of-patients-with-locally-advanced/)
- [A Real-World Data Study on the Healthcare Resource Use for Uncontrolled Moderate-to-Severe Atopic Dermatitis in Secondary Care in the United Kingdom Prior to the Introduction of Biologic Treatment](https://scholariq.org/papers/a-real-world-data-study-on-the-healthcare-resource-use-for-uncontrolled-moderate/)

## Researcher topics

- [Nonmelanoma Skin Cancer Studies](https://scholariq.org/topics/nonmelanoma-skin-cancer-studies/)
- [Hedgehog Signaling Pathway Studies](https://scholariq.org/topics/hedgehog-signaling-pathway-studies/)
- [Cancer and Skin Lesions](https://scholariq.org/topics/cancer-and-skin-lesions/)
- [Cutaneous Melanoma Detection and Management](https://scholariq.org/topics/cutaneous-melanoma-detection-and-management/)
- [Skin Protection and Aging](https://scholariq.org/topics/skin-protection-and-aging/)

## Researcher university

- [Salford Royal Hospital](https://scholariq.org/institutions/salford-royal-hospital/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.